Open AccessSystematic reviews of antihypertensive drugs: A review of publication trends, characteristics, and quality
Author(s) -
Esam Hariprasad,
Kanukula Raju,
Dhurjati Rupasvi,
Aerram Rupa,
Chevireddy Sindhujareddy,
Bhaumik Soumyadeep,
Atkins Emily,
Huffman Mark D.,
Rodgers Anthony,
Salam Abdul
Publication year - 2021
Publication title -
the journal of clinical hypertension
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.909
H-Index - 67
eISSN - 1751-7176
pISSN - 1524-6175
DOI - 10.1111/jch.14216
Subject(s) - medicine , randomized controlled trial , systematic review , publication bias , medline , protocol (science) , drug class , meta analysis , pharmacology , alternative medicine , drug , pathology , political science , law
This review presents publication trends, characteristics, and quality of systematic reviews (SRs) of randomized controlled trials (RCTs) of antihypertensive drugs (AHTDs). Between 1985 and 2017, 1,173 SRs were published, and in the last 20 years, 10, 35, and 116 were published in the year 1996, 2006, and 2016, respectively. Angiotensin‐converting enzyme inhibitors/angiotensin II receptor blockers were the most common class of drugs studied. Fourteen percent of the SRs were prospectively registered/published protocol. Three‐fourth of the SRs did not report a full search strategy, and 45% did not report a PRISMA or similar diagram. Of the 34 SRs published in the five high impact factor journals in the last 10 years, 15%, 21%, and 65% have unclear, low, and high risk of bias, respectively. There has been a steady increase in the publication of SRs of RCTs of AHTDs. However, adherence to standard methods of conduct and reporting continues to be low.